Cormorant Asset Management as of Dec. 31, 2018
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 66 positions in its portfolio as reported in the December 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Tesaro | 13.0 | $160M | 2.2M | 74.25 | |
Mirati Therapeutics | 6.0 | $74M | 1.8M | 42.42 | |
Anaptysbio Inc Common (ANAB) | 5.7 | $71M | 1.1M | 63.79 | |
Apellis Pharmaceuticals (APLS) | 4.8 | $59M | 4.5M | 13.19 | |
Inflarx Nv (IFRX) | 4.4 | $54M | 1.5M | 36.37 | |
Argenx Se (ARGX) | 3.5 | $43M | 450k | 96.07 | |
Principia Biopharma | 3.3 | $40M | 1.5M | 27.39 | |
Reata Pharmaceuticals Inc Cl A | 3.1 | $38M | 674k | 56.10 | |
Dicerna Pharmaceuticals | 3.0 | $37M | 3.5M | 10.69 | |
Sage Therapeutics (SAGE) | 2.9 | $35M | 368k | 95.79 | |
Kezar Life Sciences (KZR) | 2.7 | $34M | 1.4M | 23.60 | |
Myokardia | 2.7 | $33M | 678k | 48.86 | |
Quotient | 2.4 | $29M | 4.8M | 6.12 | |
Rocket Pharmaceuticals (RCKT) | 2.3 | $29M | 1.9M | 14.82 | |
Zogenix | 2.2 | $28M | 761k | 36.46 | |
Nektar Therapeutics (NKTR) | 2.1 | $26M | 797k | 32.87 | |
Biohaven Pharmaceutical Holding | 1.9 | $24M | 650k | 36.98 | |
Kiniksa Pharmaceuticals | 1.9 | $23M | 831k | 28.09 | |
Theravance Biopharma (TBPH) | 1.8 | $23M | 885k | 25.59 | |
Avrobio Ord (AVRO) | 1.8 | $23M | 1.4M | 16.65 | |
Ascendis Pharma A S (ASND) | 1.7 | $21M | 339k | 62.65 | |
Blueprint Medicines (BPMC) | 1.6 | $20M | 361k | 53.91 | |
Axonics Modulation Technolog (AXNX) | 1.6 | $19M | 1.3M | 15.11 | |
G1 Therapeutics | 1.6 | $19M | 994k | 19.15 | |
Zai Lab (ZLAB) | 1.5 | $18M | 787k | 23.22 | |
Solid Biosciences | 1.4 | $18M | 653k | 26.80 | |
Tricida | 1.4 | $17M | 732k | 23.58 | |
Twist Bioscience Corp (TWST) | 1.3 | $16M | 706k | 23.09 | |
Incyte Corporation (INCY) | 1.3 | $16M | 251k | 63.59 | |
Neurocrine Biosciences (NBIX) | 1.3 | $16M | 218k | 71.41 | |
Inspire Med Sys (INSP) | 1.0 | $12M | 290k | 42.25 | |
Arena Pharmaceuticals | 0.9 | $12M | 300k | 38.95 | |
Sarepta Therapeutics (SRPT) | 0.8 | $9.8M | 90k | 109.13 | |
Amarin Corporation (AMRN) | 0.8 | $9.5M | 700k | 13.61 | |
Array BioPharma | 0.7 | $8.3M | 581k | 14.25 | |
Ra Pharmaceuticals | 0.7 | $8.0M | 441k | 18.20 | |
Allakos (ALLK) | 0.6 | $7.8M | 150k | 52.27 | |
Kura Oncology (KURA) | 0.6 | $7.7M | 550k | 14.04 | |
Orchard Therapeutics Plc ads | 0.5 | $5.9M | 375k | 15.73 | |
Rubius Therapeutics | 0.5 | $5.8M | 361k | 16.08 | |
Eidos Therapeutics | 0.4 | $5.3M | 386k | 13.76 | |
Constellation Pharmceticls I | 0.4 | $5.1M | 1.3M | 4.01 | |
Scholar Rock Hldg Corp (SRRK) | 0.4 | $4.8M | 210k | 22.97 | |
Replimune Group (REPL) | 0.4 | $4.7M | 468k | 10.00 | |
Contrafect | 0.4 | $4.4M | 2.9M | 1.53 | |
Cytomx Therapeutics (CTMX) | 0.4 | $4.5M | 297k | 15.10 | |
Heron Therapeutics (HRTX) | 0.3 | $4.3M | 166k | 25.94 | |
Arsanis | 0.3 | $4.3M | 1.9M | 2.32 | |
Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.3 | $4.2M | 245k | 17.17 | |
Minerva Neurosciences | 0.3 | $4.1M | 608k | 6.74 | |
Y Mabs Therapeutics (YMAB) | 0.3 | $4.0M | 195k | 20.34 | |
Aclaris Therapeutics (ACRS) | 0.3 | $3.5M | 478k | 7.39 | |
Abeona Therapeutics | 0.3 | $3.5M | 489k | 7.14 | |
Translate Bio | 0.3 | $3.4M | 455k | 7.50 | |
Phasebio Pharmaceuticals | 0.3 | $3.4M | 1.1M | 3.09 | |
Crispr Therapeutics (CRSP) | 0.2 | $2.9M | 100k | 28.57 | |
Audentes Therapeutics | 0.2 | $2.6M | 122k | 21.32 | |
Meiragtx Holdings (MGTX) | 0.2 | $2.3M | 239k | 9.64 | |
Iterum Therapeutics | 0.2 | $2.3M | 466k | 5.01 | |
Sangamo Biosciences (SGMO) | 0.2 | $2.2M | 194k | 11.48 | |
Acceleron Pharma | 0.2 | $2.1M | 49k | 43.56 | |
Omeros Corporation (OMER) | 0.2 | $2.0M | 182k | 11.14 | |
Quanterix Ord (QTRX) | 0.1 | $1.0M | 55k | 18.31 | |
ArQule | 0.1 | $809k | 292k | 2.77 | |
Outlook Therapeutics Inc *w exp 02/18/201 | 0.0 | $63k | 417k | 0.15 | |
Cellectar Biosciences Equity Warrants *w | 0.0 | $3.2k | 53k | 0.06 |